Catalent Pharma Solutions and Sunesis Pharmaceuticals, Inc. entered into a clinical supply services agreement to support Sunesis’ Phase III trial of vosaroxin in first relapse or primary refractory acute myeloid leukemia (AML). Catalent will provide labeling and kitting of the clinical trial materials and will provide supply chain support to clinical sites. The clinical packaging and logistics will be handled in Catalent’s Philadelphia, PA and Schorndorf, Germany facilities. “As we continue t...